Cytotoxic role of advanced glycation end-products in PC12 cells treated with β‑amyloid peptide

Yan,Fu‑Ling; Han,Guo‑Ling; Wu,Guan‑Jin

doi:10.3892/mmr.2013.1545

Cytotoxic role of advanced glycation end-products in PC12 cells treated with β‑amyloid peptide

Authors:
- Fu‑Ling Yan
- Guo‑Ling Han
- Guan‑Jin Wu
View Affiliations

Affiliations: Department of Neurology, Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: June 25, 2013 https://doi.org/10.3892/mmr.2013.1545
Pages: 367-372

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD) is the most common type of dementia afflicting the elderly. Recent studies have increasingly suggested that a high concentration of advanced glycation end products (AGEs) may be important in AD pathogenesis. However, the mechanisms and pathways involved remain unknown. The aim of this study was to explore whether the mechanism of the effect of AGEs on Aβ‑PC12 cells [PC12 cells treated with β‑amyloid (Aβ) peptide] was associated with oxidative stress; and to study whether inhibiting the activity of the receptor for AGE (RAGE) attenuated the toxic effect of AGEs and Aβ on PC12 cells. Several PC12 cells were pretreated with Aβ, and were then treated with different concentrations of AGEs. Other PC12 cells were treated with trypsin, a pancreatic protein enzyme and an inhibitor of RAGE, and were then treated with Aβ and AGEs. Apoptosis was measured by flow cytometry (FCM) and cell viability was measured by MTT assay. RAGE and nuclear factor‑κB (NF‑κB) were measured by reverse transcription-polymerase chain reaction (RT‑PCR) assay. With an increase in AGE concentration, the viability of Aβ‑PC12 cells treated with AGEs decreased. However, the Aβ‑PC12 cell viability was greater in the trypsin group than in the non‑trypsin group. Cell apoptosis rates and mRNA expression of RAGE and NF‑κB in Aβ‑PC12 cells treated with AGEs were significantly higher than in the Aβ‑PC12 cells. AGEs and Aβ were neurotoxic, and RAGE triggered the neural cytotoxic role of AGEs in Aβ‑PC12 cells. The molecular mechanisms may be connected with the expression of NF‑κB and apoptosis mediated by RAGE. Inhibiting the activity of RAGE may mitigate the toxic effect of AGEs and Aβ on neural cells.

View Figures

View References

1	Jellinger KA and Attems J: Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 119:421–433. 2010. View Article : Google Scholar : PubMed/NCBI
2	Tam JH and Pasternak SH: Amyloid and Alzheimer’s disease: inside and out. Can J Neurol Sci. 39:286–298. 2012.
3	Schmidt AM, Yan SD, Yan SF and Stern DM: The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 1498:99–111. 2000. View Article : Google Scholar : PubMed/NCBI
4	Yan SD, Chen X, Fu J, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 382:685–691. 1996.
5	Bartus RT and Dean RL 3rd: Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps. Psychopharmacology (Berl). 202:15–36. 2009.
6	Lue LF, Walker DG, Brachova L, et al: Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp Neurol. 171:29–45. 2001.PubMed/NCBI
7	Yan SD, Bierhaus A, Nawroth PP and Stern DM: RAGE and Alzheimer’s disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis. 16:833–843. 2009.
8	Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 46:217–224. 2011. View Article : Google Scholar : PubMed/NCBI
9	Srikanth V, Maczurek A, Phan T, et al: Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. Neurobiol Aging. 32:763–777. 2011.
10	Kojro E and Postina R: Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer’s disease. J Alzheimers Dis. 16:865–878. 2009.PubMed/NCBI
11	Schwedler S, Schinzel R, Vaith P and Wanner C: Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl. 78:S32–S36. 2001. View Article : Google Scholar : PubMed/NCBI
12	Pike CJ, Burdick D, Walencewicz AJ, Glabe CG and Cotman CW: Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci. 13:1676–1687. 1993.PubMed/NCBI
13	Makita Z, Vlassara H, Cerami A and Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem. 267:5133–5138. 1992.PubMed/NCBI
14	Weldon DT, Maggio JE and Mantyh PW: New insights into the neuropathology and cell biology of Alzheimer’s disease. Geriatrics. 52(Suppl 2): S13–S16. 1997.
15	Maczurek A, Shanmugam K and Münch G: Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer’s disease. Ann NY Acad Sci. 1126:147–151. 2008.PubMed/NCBI
16	Perrone L, Sbai O, Nawroth PP and Bierhaus A: The complexity of sporadic Alzheimer’s disease pathogenesis: the role of RAGE as therapeutic target to promote neuroprotection by inhibiting neurovascular dysfunction. Int J Alzheimers Dis. 2012:7349562012.
17	Mucke L and Selkoe DJ: Neurotoxicity of Amyloid β-Protein: Synaptic and Network Dysfunction. Cold Spring Harb Perspect Med. 2:a0063382012.
18	Visentin S, Medana C, Barge A, Giancotti V and Cravotto G: Microwave-assisted Maillard reactions for the preparation of advanced glycation end products (AGEs). Org Biomol Chem. 8:2473–2477. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li JJ, Dickson D, Hof PR and Vlassara H: Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Mol Med. 4:46–60. 1998.PubMed/NCBI
20	Cuevas E, Lantz SM, Tobón-Velasco JC, et al: On the in vivo early toxic properties of A-beta 25–35 peptide in the rat hippocampus: involvement of the Receptor-for-Advanced Glycation-End-Products and changes in gene expression. Neurotoxicol Teratol. 33:288–296. 2011.PubMed/NCBI
21	Wilkinson K and El Khoury J: Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer’s disease. Int J Alzheimers Dis. 2012:4894562012.
22	Lue LF, Kuo YM, Beach T and Walker DG: Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol. 41:115–128. 2010.
23	Llano DA, Li J, Waring JF, et al: Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. Alzheimer Dis Assoc Disord. 26:322–328. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zhu C, Xiong Z, Chen X, et al: Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells. PLoS One. 7:e351252012.PubMed/NCBI
25	Fang F, Lue LF, Yan S, et al: RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J. 24:1043–1055. 2010.PubMed/NCBI
26	Neniskyte U, Neher JJ and Brown GC: Neuronal death induced by nanomolar amyloid β is mediated by primary phagocytosis of neurons by microglia. J Biol Chem. 286:39904–39913. 2011.
27	Cai Z, Zhao B and Ratka A: Oxidative stress and β-amyloid protein in Alzheimer’s disease. Neuromolecular Med. 13:223–250. 2011.